Ramipril-Darnitsa – inhibitor of angiotensin-converting enzyme (APF). Monokomponentna APF inhibitors.

Indications

Treatment of arterial hypertension.

Prevention of cardiovascular diseases: decrease in cardiovascular incidence and lethality at patients with:

• profound cardiovascular disease of aterotrombotichesky genesis (existence in the anamnesis of coronary heart disease or stroke or disease of peripheral vessels);
• diabetes having at least one factor of cardiovascular risk.

Treatment of a disease of kidneys:

• an initial glomerular diabetic nephropathy to which presence of a microalbuminuria testifies;
• expressed glomerular diabetic nephropathy to which presence of a macroproteinuria, at the patients having at least one factor of cardiovascular risk testifies;
• expressed glomerular not diabetic nephropathy to which presence of a macroproteinuria ≥ 3 g/days

Treatment of the heart failure which is followed by clinical manifestations.

Secondary prevention after the postponed acute myocardial infarction: reduction of lethality during the acute stage of a myocardial infarction at patients with clinical signs of heart failure at an initiation of treatment more than in 48 hours after developing of an acute myocardial infarction.

Structure

• active ingredient: ramiprit;
1 tablet contains
• ramiprit 10 mg;
• other components: a gipromeloza, starch prezhelatinizirovanny, cellulose microcrystalline, the sodium stearylfumarating.

Contraindication

• Hypersensitivity to active ingredient or any of the excipients which are a part of medicine or other APF inhibitors (angiotensin-converting enzyme).
• Existence in the anamnesis of a Quincke's disease (the hereditary, idiopathic or earlier postponed against the background of use APF inhibitors or antagonists of receptors of angiotensin II).
• Simultaneous use with sakubitrilom/valsartany.
bilateral stenosis of renal arteries or a renal artery stenosis in the presence of the only functioning kidney Is considerable
• .
• Ramipril should not be applied to patients with arterial hypotension or hemodynamically unstable states.
to
• Simultaneous use of Ramipril-Darnitsa medicine with the medicines containing aliskiren is contraindicated to patients with diabetes or renal dysfunction (the glomerular filtration rate (GFR) <60 ml/min. / 1.73 to sq.m).
• needs to avoid simultaneous use of APF inhibitors and extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces.
• Pregnancy and planning of pregnancy.

Side reactions

Profile of safety of Ramipril-Darnitsa medicine contains data on constant cough and the reactions caused by arterial hypotension. The Quincke's disease, a hyperpotassemia, an abnormal liver function or kidneys, pancreatitis, heavy reactions belong to serious side reactions from skin and a neutropenia/agranulocytosis.

Route of administration

Medicine for oral administration.

is recommended to be accepted daily at the same time. Medicine can be accepted to, in time and after a meal as food does not affect bioavailability of medicine. The tablets Ramipril-Darnitsa should be swallowed entirely, washing down with water. They cannot be chewed or crushed.

At impossibility of use of the appointed dose to apply in the corresponding dosage.

Feature of use

Use during pregnancy or feeding by a breast

Pregnancy. It is contraindicated to pregnant women or women who are going to become pregnant to apply medicine.

due to the lack of information on use of a ramipril during feeding a breast this medicine to women who nurse, and it is desirable to give preference to other medicines which use during a lactation is safer, especially at chest feeding of newborn or premature babies.

Children

Ramipril-Darnitsa Medicine is not recommended to be applied to children (up to 18 years) as data on efficiency and safety of this medicine for such patients are not enough.

Ability to influence speed of response at control of motor transport or other mechanisms

Some side effects (for example, symptoms of decrease in the ABP, such as dizziness) can break ability of the patient to concentration of attention and reduce the speed of its reaction that is risky in situations when these qualities are of especially great importance (for example, at control of vehicles or work with other mechanisms).

Symptoms connected with overdose of APF inhibitors an excessive peripheral vazodilatation (with the profound arterial hypotension, shock), bradycardia, disturbance of electrolytic balance and a renal failure can be p>

. Behind a condition of the patient it is necessary to observe and carry out symptomatic and maintenance therapy carefully. Primary detoxication (gastric lavage, administration of adsorbents) and also the measures directed to restoration of a stable hemodynamics, including administration of agonists alpha 1 - adrenoceptors or angiotensin II (Angiotensinamidum) belong to the proposed medical measures. Ramiprilat, an active metabolite of a ramipril, is badly brought from a system blood-groove by a hemodialysis.

Storage conditions

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.